secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2026-06-04T20:05:17+00:00
Accession:  0001193125-26-257376
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum cuts workforce 85% after SCD drug failure; hires Leerink for strategic review
--------------------------------------------------------------------------------

- Workforce reduced from 57 to 9 employees (~85% cut) after discontinuing pociredir for sickle cell disease.
- Expects ~$4.2M in restructuring charges (severance, benefits) mostly in Q2 2026.
- Engaged Leerink Partners as financial advisor to explore strategic alternatives including merger or sale.
- No timeline set for strategic review; no assurance of any transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312526257376/0001193125-26-257376-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312526257376/fulc-20260531.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-257376

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer